2020 American Transplant Congress
Myeloid Derived Suppressor Cells Expanded by Granulocyte-Colony Stimulating Factor Prolong Allogeneic Cardiac Graft Survival When Compared with MDSCs Expanded by Different Means
Department of Surgery, University of Maryland, Baltimore, MD
*Purpose: Myeloid-derived suppressor cells (MDSCs) inhibit T cell responses and may provide a pathway towards tolerance. Granulocyte-colony stimulating factor (GCSF) is used in clinical practice…2020 American Transplant Congress
Everolimus for BKV Nephropathy in Kidney Transplant Recipients: A Prospective, Controlled Study
*Purpose: Polyoma BK virus nephropathy (BKVN) of KTRs is associated with adverse outcome, since no specific therapy exists. EVR showed promising antiviral effects but systematic…2020 American Transplant Congress
Introduction of Preemptive Pharmacogenomic Testing in Kidney Transplant Recipients: Early Evaluation of the Clinical Impact of Genomic Guided Tacrolimus Dosing
*Purpose: Tacrolimus is widely accepted as the mainstay of immunosuppression in solid organ transplant. Inherited differences in CYP3A activity are known to contribute to dosing…2020 American Transplant Congress
Pre-Transplant Pharmacogenetics Identifies CYP3A4 and CYP3A5 Heterogeneity among Caucasian Kidney Transplant Recipients
*Purpose: Tacrolimus has always been dosed based on therapeutic drug monitoring, however pharmacogenomics is becoming increasingly more utilized in the era of precision based medicine…2020 American Transplant Congress
Targeting Th17: TIGIT as a Key Regulator of Tregs/Th17 Cells in Belatacept Resistant Rejection
Emory University Transplant Center, Emory University, Atlanta, GA
*Purpose: Belatacept resistant-rejection (BRR) is a major barrier to the widespread adoption of immune checkpoint blockade therapeutics in transplantation. Our lab has shown that patients…2020 American Transplant Congress
Survival after Lung Transplantation by Discharge Immunosuppressive Regimen: An Analysis of Organ Procurement and Transplantation Network Data
*Purpose: As the optimal immunosuppressive (IS) regimen after lung (LU) transplant (TX) is unknown, we conducted an analysis to compare the effect of four different…2020 American Transplant Congress
Clinical Outcomes from a Mobile Health, Pharmacist-Led Intervention: 12-Month Results of the Transafe Rx Randomized Controlled Trial
Med Univ of South Carolina, Charleston, SC
*Purpose: Medication errors and non-adherence are predominant causes of poor graft outcomes in kidney transplant (KTX) recipients. The primary aim of the TRANSAFE Rx RCT…2020 American Transplant Congress
Belatacept Suppresses the B-Cell Alloresponse in the Lower Range of Therapeutic Trough Concentrations
1Plexision, Pittsburgh, PA, 2Bristol-Myers-Squibb, Princeton, NJ
*Purpose: Background: Kidney recipients treated with the T-cell costimulation blocker, belatacept, experience a higher incidence of acute cellular rejection (ACR) and lower incidence of donor-specific…2020 American Transplant Congress
Pharmacokinetic Evaluation of a De Novo Envarsus XR® (tacrolimus Extended Release) Dosing Strategy in Kidney Transplant Recipients
*Purpose: Envarsus XR® is a once-daily tablet formulation of tacrolimus recently approved for the prophylaxis of organ rejection in de novo kidney transplant recipients (KTx).…2020 American Transplant Congress
Kidney Transplant Recipients with De Novo Donor Specific Antibody is Associated with Increased Risk of Developing BK Viremia
*Purpose: Background: De novo donor specific anti-HLA antibodies (dnDSA) has profound effect on the renal graft long-term function and survival. Studies has shown identifications of…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 138
- Next Page »